Connexion
E-mail
Mot de passe
Afficher le mot de passe
Retenir
Mot de passe oublié ?
Devenir membre gratuitement
Inscription
Inscription
Devenir membre
Inscription gratuite
Devenir client
Découvrez nos services
Paramètres
Paramètres
Cotations dynamiques 
OFFON

SAREPTA THERAPEUTICS, INC.

(SRPT)
  Rapport
SynthèseCotationsGraphiquesActualitésNotationsAgendaSociétéFinancesConsensusRévisionsDérivésFondsCommunauté 
SynthèseToute l'actualitéReco analystesAutres languesCommuniquésPublications officiellesActualités du secteur
Actualités dans d'autres langues sur SAREPTA THERAPEUTICS, INC.
15/10SAREPTA THERAPEUTICS : Announces Preliminary Financial Results for the Third Quarter Ended..
15/10SAREPTA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Results of Operat..
14/10SAREPTA THERAPEUTICS : Prices Public Offering at $81/Share, Expects $500 Million Gross Pro..
14/10SAREPTA THERAPEUTICS : Announces Pricing of $500 Million Public Offering of Common Stock
14/10Sarepta Therapeutics Announces Pricing of $500 Million Public Offering of Common Stock
13/10Health Care Stocks Edging Higher Ahead of Wednesday Close
13/10SAREPTA THERAPEUTICS : Cash Levels Drop From Year-End 2020; Shares Down
12/10SAREPTA THERAPEUTICS : Estimates Higher Q3 Product Revenue
12/10SAREPTA THERAPEUTICS : Starts $500 Million Common Stock Offering
12/10SAREPTA THERAPEUTICS : Announces Preliminary Financial Results for the Third Quar-ter Ende..
12/10SAREPTA THERAPEUTICS : Announces Proposed $500,000,000 Public Offering of Common Stock
12/10Sarepta Therapeutics, Inc. Reports Preliminary Revenue Guidance for the Third Quarter E..
11/10SAREPTA THERAPEUTICS' : Muscular Dystrophy Drug Shows Potential in Late-Stage Trial
11/10SAREPTA THERAPEUTICS : ' SRP-9001 Shows Sustained Functional Improvements in Multiple Stud..
11/10Sarepta Therapeutics’ SRP-9001 Shows Sustained Functional Improvements in Multiple Stud..
08/10CODIAK BIOSCIENCES : Says Sarepta Therapeutics Terminates Research License, Option Agreeme..
04/10SAREPTA THERAPEUTICS : Opens Genetic Therapies Center of Excellence in Columbus, Ohio
04/10Sarepta Therapeutics, Inc. Opens Genetic Therapies Center of Excellence in Columbus, Oh..
04/10SAREPTA THERAPEUTICS : Commences SRP-9001 Study in Duchenne Muscular Dystrophy
04/10SAREPTA THERAPEUTICS : Announces Initiation of EMBARK, a Global Pivotal Study of SRP-9001,..
04/10Sarepta Therapeutics Announces Initiation of EMBARK, Study of SRP-9001, a Gene Therapy ..
04/10ANTISENSE THERAPEUTICS LIMITED : Antisense Therapeutics ernennt neuen Non-Executive Direct..
01/10SAREPTA THERAPEUTICS : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
27/09SAREPTA THERAPEUTICS : to Initiate Part B of MOMENTUM Study of SRP-5051 in Patients with D..
27/09SAREPTA THERAPEUTICS : to Initiate Part B of Study Into Duchenne Muscular Dystrophy Treatm..
27/09SAREPTA THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (..
27/09Sarepta Therapeutics, Inc. to Initiate Part B of Momentum Study of SRP-5051 in Patients..
27/09Sarepta Therapeutics to Initiate Part B of MOMENTUM Study of SRP-5051 in Patients with ..
24/09PRESS RELEASE : Roche presents new data at World Muscle Society (WMS) 2021 highlighting ne..
20/09SEROPREVALENCE : What patients should know about pre-existing antibodies to gene therapy
20/09SELECTA BIOSCIENCES : Names Kevin Tan Finance Chief
20/09SELECTA BIOSCIENCES : Hires Kevin Tan as CFO
20/09SAREPTA THERAPEUTICS, INC.(NASDAQGS : SRPT) dropped from FTSE All-World Index
14/09SAREPTA THERAPEUTICS : to Showcase Data from its Gene Therapy and RNA Platforms at World M..
09/09SAREPTA THERAPEUTICS : LBP.22 Mercuri et al. Safety tol and PK of etep in pts 6-48 mon wit..
09/09SAREPTA THERAPEUTICS : EP.096 Peterson et al. Micro-dystrophin gene transfer therapy and T..
09/09SAREPTA THERAPEUTICS : EP.149 Iff et al. Delay in DMD prog with eteplirsen longer time to ..
07/09SAREPTA THERAPEUTICS : to Present at Upcoming Investor Conferences
07/09SAREPTA THERAPEUTICS : Announces Recipients of Route 79, The Duchenne Scholarship Program
07/09SAREPTA THERAPEUTICS : EP.254 Mendell et al. SRP-9001-102 eval safety and efficacy in DMD
31/08Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
27/08SAREPTA THERAPEUTICS : Measurements Used in Clinical Trials for Duchenne Muscular Dystroph..
11/08SAREPTA THERAPEUTICS : MIT- Machine learning discovers new sequences to boost drug deliver..
06/08NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
04/08SAREPTA THERAPEUTICS : 2Q 2021 Forward Looking Statement
04/08SAREPTA THERAPEUTICS : Q2 Earnings Snapshot
04/08SAREPTA THERAPEUTICS : Earnings Flash (SRPT) SAREPTA THERAPEUTICS Reports Q2 Loss $-1.52, ..
04/08SAREPTA THERAPEUTICS : Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q2 Revenue $164.1M..
04/08SAREPTA THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Res..
04/08SAREPTA THERAPEUTICS : Announces Second Quarter 2021 Financial Results and Recent Corporat..
04/08Sarepta Therapeutics, Inc. Raises Product Revenue Guidance for Full Year of 2021
04/08Sarepta Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 3..
04/08SAREPTA THERAPEUTICS : Strikes Licensing Deal For Therapy Candidate Calpain 3 to Treat Lim..
04/08EARNINGS REACTION HISTORY : Sarepta Therapeutics Inc, 72.7% Follow-Through Indicator, 4.8%..
04/08Sarepta Therapeutics Executes Licensing Agreement for Gene Therapy Program from Nationw..
04/08Sarepta Therapeutics, Inc. Executes Licensing Agreement for Gene Therapy Program from N..
30/07Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
28/07SAREPTA THERAPEUTICS : to Announce Second Quarter 2021 Financial Results and Recent Corpor..
19/07PASSAGE BIO : Names New Finance, Medical Chiefs
01/07Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29/06INSIDER TRENDS : Insider at Sarepta Therapeutics Sale for Taxes Adds to 90-Day Selling Tre..
03/06SAREPTA THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K..
03/06Sarepta Therapeutics to Present at Upcoming Investor Conferences
29/05Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18/05Walmart, Sarepta rise; Chevron, D.R. Horton fall
18/05SECTOR UPDATE : Health Care Stocks Adding to Small Afternoon Gains
18/05SECTOR UPDATE : Health Care Stocks Posting Modest Gains
18/05SAREPTA THERAPEUTICS' : Investigational Gene Therapy SRP-9001 Demonstrates Positive Result..
18/05SAREPTA THERAPEUTICS : Results from the first 11 participants enrolled in Study 9001-103 E..
18/05SAREPTA THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (..
18/05SAREPTA THERAPEUTICS : Clinical Update Micro-dystrophin SRP-9001-103_05.18.2021
18/05Sarepta Therapeutics' Investigational Gene Therapy for the Treatment of Duchenne Muscul..
18/05Sarepta Therapeutics, Inc. Announces Positive 12-Week Expression and Safety Results fro..
17/05Sarepta Therapeutics to Share Expression and Safety Results from Study 103 (ENDEAVOR) E..
12/05SAREPTA THERAPEUTICS : ASGCT 2021_Rodino-Klapac et al._Safety Exp & Funct Outcomes SRP-900..
1  2  3  4  5  6  7  8  9  10Suiv.
Prochain événement sur SAREPTA THERAPEUTICS, INC.